Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380302 · ClinicalTrials.gov registry record · Phase 1
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT00380302: Completed Phase 1 study, sponsored by Sanofi.
NCT00380302 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 162 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380302, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill). Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.
Interventions
- DRUG AVE1625
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00380302 record still lists
NCT00380302 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (170% higher).
The record links to 0 conditions, and to 1 intervention - of which AVE1625 is the first listed.
NCT00380302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00380302 about?
NCT00380302 is a clinical study titled "Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.". Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill). Secondary:The stu...
What is the current status of trial NCT00380302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2006-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00380302?
The interventions under investigation include: AVE1625 (DRUG).
Who is sponsoring clinical trial NCT00380302?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00380302's enrollment target sits among peer trials
162 336th of 2000 higher than 1,661 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia